Answer
In clinical studies of adults with Fabry disease, pegunigalsidase alfa had a plasma half-life of 53–134 hours across dose groups and visit days.
Sources for this answer
- Elfabrio 2 mg/mL concentrate for solution for infusionChiesi Limited · emc · SmPC §5.2 Pharmacokinetic properties · Version 3Document updated
Sources checked